Dapagliflozin in heart failure with preserved and mildly reduced ejection fraction: rationale and design of the <scp>DELIVER</scp> trial - Concepedia

Concepedia

Publication | Open Access

Dapagliflozin in heart failure with preserved and mildly reduced ejection fraction: rationale and design of the <scp>DELIVER</scp> trial

DOI Full Paper Access

307

Citations

29

References

2021

Year

Scott D. Solomon, Rudolf A. de Boer, David L. DeMets, Adrian F. Hernandez, Silvio E. Inzucchi, Mikhail Kosiborod, Carolyn S.P. Lam, Felipe A. Martínez, Sanjiv J. Shah, Daniel Lindholm,

European Journal of Heart Failure

Abstract

DELIVER will determine the efficacy and safety of the SGLT2 inhibitor dapagliflozin, added to conventional therapy, in patients with heart failure and preserved and mildly reduced ejection fraction.

References

	Year	Citations

Page 1